InVitria's Recombinant Albumin-DX eliminates safety concerns, stabilizes sensitive biomarkers and enhances diagnostic performance by improving specificity.
Fort Collins, CO (PRWEB) April 2, 2009 -- Addressing significant product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products. InVitria's Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA).
The advantages of Recombinant Albumin-DX include:
"InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise," said the company's President and CEO Scott Deeter. "Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek."
To receive a Recombinant Albumin-DX or DX Lipid-Free product materials packet, please contact InVitria's customer service specialists at 1-800-916-8311 or by e-mail at info@InVitria.com.
About InVitria
InVitria develops, manufactures and markets a portfolio of cell culture and diagnostic reagents. These products are used in cell culture, biopharmaceutical formulation, stem cell & regenerative medicine, medical devices and diagnostics.
Learn more about InVitria's products at http://www.invitria.com [Diagnostics__title__InVitria
###
Read the full story at http://www.prweb.com/releases/diagnostics/InVitria/prweb2291484.htm.
Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved |